Biotech and especially the Big Four of Celgene, Amgen, Gilead, and Biogen have been on an absolute tear the past couple days to add to their already large gains YTD. I play this sector by the Rydex biotech fund (RYOIX) if only because it is pretty evenly spread among the Big Four as opposed to some biotech funds which are overweight one or the other. With baby boomers turning 65 every 8 seconds it not hard to see why there is so much enthusiam for this sector going forward. Then again, the biotech boom has been in full force for over 10 years now.
Actually, the healthcare area that is the most on fire YTD and all thanks to next year's Obamacare are the hospital stocks - UHS, CYH, THC, HCA, and LPNT. I missed that area completely being asleep at the wheel.
Comments
Regards,
Ted
Come to think of it, that might be a good topic for a thread....what is your longest held fund, and why has it stayed in your portfolio?
Here are two charted together over the last 8 years:
Regards,
Ted
Bee, M* doesn't show the same result starting with the VGHCX chart: since early 2004, at VHT's inception, the $10k invested-total return chart shows VGHCX at $21,314 and VHT at $18,260. The 1y chart does show the ETF with a little better return.
If you started with the ETF chart, I think that gives you price/NAV, not total return. To get TR with M*, you have to start with the OEF chart and add the ETF to it. Yep, another weird M* thing.
Here is comparison:
Ditto for VDE and VGENX on the energy side. The former is an index, while the latter is actively managed.
That said, both ETFs provide good sector exposure for low cost and with good liquidity.
I'm getting more interested in ETFs these days. I recently started buying BOND because it is strategic proxy to PTTRX.
Thanks in advance. I have been doing DCA inti PRHSX from 2009 or so. At 60 yo, what should be the final weightage (currently at 8%) to aim for?(in a moderate risk portfolio per MF)? No need to withdraw for some years after retirement
He doesn't make specific predictions or recommendations like the loud-talking financial commentariat, but more on the order of pointing out what's a reasonable valuation or not for a possible long-term investment, leaving it up to us to decide if it works in our individual situations.
On the basis of PE10s, the U.S. market as a whole is overvalued vs. the long-term median. That doesn't mean, of course, that it can't keep going up, especially in this, um, unique econ environment.